Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.

Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW.

JNCI Cancer Spectr. 2018 Nov;2(4):pky062. doi: 10.1093/jncics/pky062. Epub 2018 Dec 24.

2.

Evidence-based sizing of non-inferiority trials using decision models.

Lansdorp-Vogelaar I, Jagsi R, Jayasekera J, Stout NK, Mitchell SA, Feuer EJ.

BMC Med Res Methodol. 2019 Jan 7;19(1):3. doi: 10.1186/s12874-018-0643-2.

3.

Long-Term Survivorship Care After Cancer Treatment: A New Emphasis on the Role of Rehabilitation Services.

Stout NL, Silver JK, Alfano CM, Ness KK, Gilchrist LS.

Phys Ther. 2019 Jan 1;99(1):10-13. doi: 10.1093/ptj/pzy115.

PMID:
30329114
4.

How Registry Data Will Change Our Approach to Lymphedema Research and Clinical Management.

Stout NL.

Rehabil Oncol. 2018 Jan;36(1):73-75. doi: 10.1097/01.REO.0000000000000108.

5.

The effect of mammography screening regimen on incidence-based breast cancer mortality.

Yaffe MJ, Mittmann N, Alagoz O, Trentham-Dietz A, Tosteson AN, Stout NK.

J Med Screen. 2018 Dec;25(4):197-204. doi: 10.1177/0969141318780152. Epub 2018 Jul 26.

PMID:
30049249
6.

A Bibliometric Analysis of the Landscape of Cancer Rehabilitation Research (1992-2016).

Stout NL, Alfano CM, Belter CW, Nitkin R, Cernich A, Lohmann Siegel K, Chan L.

J Natl Cancer Inst. 2018 Aug 1;110(8):815-824. doi: 10.1093/jnci/djy108.

7.

Estrogen-receptor status and risk of contralateral breast cancer following DCIS.

Stout NK, Cronin AM, Uno H, Ozanne EM, Hassett MJ, Frank ES, Greenberg CC, Punglia RS.

Breast Cancer Res Treat. 2018 Oct;171(3):777-781. doi: 10.1007/s10549-018-4860-5. Epub 2018 Jun 26.

PMID:
29946862
8.

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer.

Jayasekera J, Li Y, Schechter CB, Jagsi R, Song J, White J, Luta G, Chapman JW, Feuer EJ, Zellars RC, Stout N, Julian TB, Whelan T, Huang X, Shelley Hwang E, Hopkins JO, Sparano JA, Anderson SJ, Fyles AW, Gray R, Sauerbrei W, Mandelblatt J, Berry DA; CISNET-BOLD Collaborative Group .

J Natl Cancer Inst. 2018 Dec 1;110(12):1360-1369. doi: 10.1093/jnci/djy059.

PMID:
29718314
9.

Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.

Christensen KD, Vassy JL, Phillips KA, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D.

Genet Med. 2018 Mar 22. doi: 10.1038/gim.2018.35. [Epub ahead of print]

10.

Ventral pallidal encoding of reward-seeking behavior depends on the underlying associative structure.

Richard JM, Stout N, Acs D, Janak PH.

Elife. 2018 Mar 22;7. pii: e33107. doi: 10.7554/eLife.33107.

11.

Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Alagoz O, Berry DA, de Koning HJ, Feuer EJ, Lee SJ, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A, Mandelblatt JS; CISNET Breast Cancer Working Group members.

Med Decis Making. 2018 Apr;38(1_suppl):3S-8S. doi: 10.1177/0272989X17737507.

PMID:
29554472
12.

Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Cevik M, Schechter CB, Lee SJ, Huang H, Li Y, Munoz DF, Plevritis SK, de Koning HJ, Stout NK, van Ballegooijen M.

Med Decis Making. 2018 Apr;38(1_suppl):112S-125S. doi: 10.1177/0272989X17743244.

PMID:
29554471
13.

The University of Wisconsin Breast Cancer Epidemiology Simulation Model: An Update.

Alagoz O, Ergun MA, Cevik M, Sprague BL, Fryback DG, Gangnon RE, Hampton JM, Stout NK, Trentham-Dietz A.

Med Decis Making. 2018 Apr;38(1_suppl):99S-111S. doi: 10.1177/0272989X17711927.

PMID:
29554470
14.

Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

van den Broek JJ, van Ravesteyn NT, Mandelblatt JS, Huang H, Ergun MA, Burnside ES, Xu C, Li Y, Alagoz O, Lee SJ, Stout NK, Song J, Trentham-Dietz A, Plevritis SK, Moss SM, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):140S-150S. doi: 10.1177/0272989X17718168.

PMID:
29554468
15.

Contribution of Breast Cancer to Overall Mortality for US Women.

Gangnon RE, Stout NK, Alagoz O, Hampton JM, Sprague BL, Trentham-Dietz A.

Med Decis Making. 2018 Apr;38(1_suppl):24S-31S. doi: 10.1177/0272989X17717981.

PMID:
29554467
16.

Cost-effectiveness of mammography from a publicly funded health care system perspective.

Mittmann N, Stout NK, Tosteson ANA, Trentham-Dietz A, Alagoz O, Yaffe MJ.

CMAJ Open. 2018 Feb 8;6(1):E77-E86. doi: 10.9778/cmajo.20170106.

17.

Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer.

Buist DSM, Abraham L, Lee CI, Lee JM, Lehman C, O'Meara ES, Stout NK, Henderson LM, Hill D, Wernli KJ, Haas JS, Tosteson ANA, Kerlikowske K, Onega T; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):458-468. doi: 10.1001/jamainternmed.2017.8549.

PMID:
29435556
18.

Using Collaborative Simulation Modeling to Develop a Web-Based Tool to Support Policy-Level Decision Making About Breast Cancer Screening Initiation Age.

Burnside ES, Lee SJ, Bennette C, Near AM, Alagoz O, Huang H, van den Broek JJ, Kim JY, Ergun MA, van Ravesteyn NT, Stout NK, de Koning HJ, Mandelblatt JS.

MDM Policy Pract. 2017 Jul;2. doi: 10.1177/2381468317717982. Epub 2017 Jul 8.

19.

Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, Lee SJ, van den Broek JJ, Huang X, Schechter CB, Sprague BL, Song J, de Koning HJ, Trentham-Dietz A, van Ravesteyn NT, Gangnon R, Chandler Y, Li Y, Xu C, Ergun MA, Huang H, Berry DA, Mandelblatt JS.

JAMA. 2018 Jan 9;319(2):154-164. doi: 10.1001/jama.2017.19130. Erratum in: JAMA. 2018 Feb 20;319(7):724.

20.

Distinguishing between CISNET model results versus CISNET models.

Berry DA, de Koning HJ, Lee SJ, Mandelblatt JS, Plevritis SK, Schechter CB, Stout NK, Trentham-Dietz A; CISNET Breast Working Group Principal Investigators.

Cancer. 2018 Mar 1;124(5):1083-1084. doi: 10.1002/cncr.31150. Epub 2017 Dec 26. No abstract available.

PMID:
29278430
21.

Utilization of breast cancer screening with magnetic resonance imaging in community practice.

Hill DA, Haas JS, Wellman R, Hubbard RA, Lee CI, Alford-Teaster J, Wernli KJ, Henderson LM, Stout NK, Tosteson ANA, Kerlikowske K, Onega T.

J Gen Intern Med. 2018 Mar;33(3):275-283. doi: 10.1007/s11606-017-4224-6. Epub 2017 Dec 6.

PMID:
29214373
22.

Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.

Trentham-Dietz A, Ergun MA, Alagoz O, Stout NK, Gangnon RE, Hampton JM, Dittus K, James TA, Vacek PM, Herschorn SD, Burnside ES, Tosteson ANA, Weaver DL, Sprague BL.

Breast Cancer Res Treat. 2018 Feb;168(1):229-239. doi: 10.1007/s10549-017-4582-0. Epub 2017 Nov 28.

PMID:
29185118
23.

Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study.

Rutter CM, Kim JJ, Meester RGS, Sprague BL, Burger EA, Zauber AG, Ergun MA, Campos NG, Doubeni CA, Trentham-Dietz A, Sy S, Alagoz O, Stout N, Lansdorp-Vogelaar I, Corley DA, Tosteson ANA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):158-164. doi: 10.1158/1055-9965.EPI-17-0378. Epub 2017 Nov 17.

PMID:
29150480
24.

Emerging Trends in Family History of Breast Cancer and Associated Risk.

Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, Buist DSM, Egan KM, Newcomb PA, Trentham-Dietz A.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1753-1760. doi: 10.1158/1055-9965.EPI-17-0531. Epub 2017 Oct 6.

25.

A Focused Review of Safety Considerations in Cancer Rehabilitation.

Maltser S, Cristian A, Silver JK, Morris GS, Stout NL.

PM R. 2017 Sep;9(9S2):S415-S428. doi: 10.1016/j.pmrj.2017.08.403. Review.

26.

A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017).

Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J.

PM R. 2017 Sep;9(9S2):S347-S384. doi: 10.1016/j.pmrj.2017.07.074. Review.

27.

Expanding the Perspective on Chemotherapy-Induced Peripheral Neuropathy Management.

Stout NL.

J Clin Oncol. 2017 Aug 10;35(23):2593-2594. doi: 10.1200/JCO.2017.73.6207. Epub 2017 Jun 6. No abstract available.

PMID:
28586245
28.

Tweet this: how advocacy for breast and prostate cancers stacks up on social media.

Loeb S, Stork B, Gold HT, Stout NK, Makarov DV, Weight CJ, Borgmann H.

BJU Int. 2017 Oct;120(4):461-463. doi: 10.1111/bju.13908. Epub 2017 Jun 7. No abstract available.

29.

Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.

Wong SM, Stout NK, Punglia RS, Prakash I, Sagara Y, Golshan M.

Cancer. 2017 Jul 15;123(14):2609-2617. doi: 10.1002/cncr.30644. Epub 2017 Feb 21.

30.

Surgical Prehabilitation in Patients with Cancer: State-of-the-Science and Recommendations for Future Research from a Panel of Subject Matter Experts.

Carli F, Silver JK, Feldman LS, McKee A, Gilman S, Gillis C, Scheede-Bergdahl C, Gamsa A, Stout N, Hirsch B.

Phys Med Rehabil Clin N Am. 2017 Feb;28(1):49-64. doi: 10.1016/j.pmr.2016.09.002. Review.

PMID:
27913000
31.

Toward a National Initiative in Cancer Rehabilitation: Recommendations From a Subject Matter Expert Group.

Stout NL, Silver JK, Raj VS, Rowland J, Gerber L, Cheville A, Ness KK, Radomski M, Nitkin R, Stubblefield MD, Morris GS, Acevedo A, Brandon Z, Braveman B, Cunningham S, Gilchrist L, Jones L, Padgett L, Wolf T, Winters-Stone K, Campbell G, Hendricks J, Perkin K, Chan L.

Arch Phys Med Rehabil. 2016 Nov;97(11):2006-2015. doi: 10.1016/j.apmr.2016.05.002. Epub 2016 May 27.

PMID:
27237580
32.

Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.

Trentham-Dietz A, Kerlikowske K, Stout NK, Miglioretti DL, Schechter CB, Ergun MA, van den Broek JJ, Alagoz O, Sprague BL, van Ravesteyn NT, Near AM, Gangnon RE, Hampton JM, Chandler Y, de Koning HJ, Mandelblatt JS, Tosteson AN; Breast Cancer Surveillance Consortium and the Cancer Intervention and Surveillance Modeling Network.

Ann Intern Med. 2016 Nov 15;165(10):700-712. doi: 10.7326/M16-0476. Epub 2016 Aug 23.

33.

Association of Regional Intensity of Ductal Carcinoma In Situ Treatment With Likelihood of Breast Preservation.

Punglia RS, Cronin AM, Uno H, Stout NK, Ozanne EM, Greenberg CC, Frank ES, Schrag D.

JAMA Oncol. 2017 Jan 1;3(1):101-104. doi: 10.1001/jamaoncol.2016.2164.

PMID:
27442038
34.

Tilt testing: it may be safe but is it any good?

Stout N.

Age Ageing. 2016 Mar;45(2):186-7. doi: 10.1093/ageing/afw011. No abstract available.

PMID:
26941351
35.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

36.

Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status.

Haas JS, Hill DA, Wellman RD, Hubbard RA, Lee CI, Wernli KJ, Stout NK, Tosteson AN, Henderson LM, Alford-Teaster JA, Onega TL.

Cancer. 2016 Feb 15;122(4):611-7. doi: 10.1002/cncr.29805. Epub 2015 Dec 28.

37.

Total cost-effectiveness of mammography screening strategies.

Mittmann N, Stout NK, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Yaffe MJ.

Health Rep. 2015 Dec;26(12):16-25.

38.

Clinical outcomes of modelling mammography screening strategies.

Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK.

Health Rep. 2015 Dec;26(12):9-15.

39.

Modelling mammography screening for breast cancer in the Canadian context: Modification and testing of a microsimulation model.

Yaffe MJ, Mittmann N, Lee P, Tosteson AN, Trentham-Dietz A, Alagoz O, Stout NK.

Health Rep. 2015 Dec;26(12):3-8.

40.

Cancer Models and Real-world Data: Better Together.

Kim JJ, Tosteson AN, Zauber AG, Sprague BL, Stout NK, Alagoz O, Trentham-Dietz A, Armstrong K, Pruitt SL, Rutter CM; Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium.

J Natl Cancer Inst. 2015 Nov 3;108(2). pii: djv316. doi: 10.1093/jnci/djv316. Print 2016 Feb.

41.

onlineDeCISion.org: a web-based decision aid for DCIS treatment.

Ozanne EM, Schneider KH, Soeteman D, Stout N, Schrag D, Fordis M, Punglia RS.

Breast Cancer Res Treat. 2015 Nov;154(1):181-90.

PMID:
26475704
42.

Using Active Learning for Speeding up Calibration in Simulation Models.

Cevik M, Ergun MA, Stout NK, Trentham-Dietz A, Craven M, Alagoz O.

Med Decis Making. 2016 Jul;36(5):581-93. doi: 10.1177/0272989X15611359. Epub 2015 Oct 15.

43.

Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007.

Weinmann S, Williams AE, Kamineni A, Buist DS, Masterson EE, Stout NK, Stark A, Ross TR, Owens CL, Field TS, Doubeni CA.

Cancer. 2015 Sep 1;121(17):2976-83. doi: 10.1002/cncr.29445. Epub 2015 May 18.

44.

Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ.

J Natl Cancer Inst. 2015 May 6;107(7). pii: djv103. doi: 10.1093/jnci/djv103. Print 2015 Jul.

45.

Pharmacogenomic test that predicts response to inhaled corticosteroids in adults with asthma likely to be cost-saving.

Wu AC, Gay C, Rett MD, Stout N, Weiss ST, Fuhlbrigge AL.

Pharmacogenomics. 2015;16(6):591-600. doi: 10.2217/pgs.15.28. Epub 2015 Apr 16.

46.

The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model.

Gangnon RE, Sprague BL, Stout NK, Alagoz O, Weedon-Fekjær H, Holford TR, Trentham-Dietz A.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):905-12. doi: 10.1158/1055-9965.EPI-14-1286. Epub 2015 Mar 18.

47.

Practical clinical interventions for diet, physical activity, and weight control in cancer survivors.

Demark-Wahnefried W, Rogers LQ, Alfano CM, Thomson CA, Courneya KS, Meyerhardt JA, Stout NL, Kvale E, Ganzer H, Ligibel JA.

CA Cancer J Clin. 2015 May-Jun;65(3):167-89. doi: 10.3322/caac.21265. Epub 2015 Feb 13. Review.

48.

Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts.

Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, Lee CI, van den Broek JJ, Miglioretti DL, Mandelblatt JS, de Koning HJ, Kerlikowske K, Lehman CD, Tosteson AN.

Ann Intern Med. 2015 Feb 3;162(3):157-66. doi: 10.7326/M14-0692.

49.

Recent progress in the treatment and prevention of cancer-related lymphedema.

Shaitelman SF, Cromwell KD, Rasmussen JC, Stout NL, Armer JM, Lasinski BB, Cormier JN.

CA Cancer J Clin. 2015 Jan-Feb;65(1):55-81. doi: 10.3322/caac.21253. Epub 2014 Nov 19. Review. Erratum in: CA Cancer J Clin. 2015 May-Jun;65(3):252.

50.

Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts.

Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD.

Radiology. 2015 Mar;274(3):772-80. doi: 10.1148/radiol.14141237. Epub 2014 Oct 28.

Supplemental Content

Support Center